Opinion on Therapy Area in France

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Pain: on the increase

Published By Datamonitor
19 Mar 2001
Expert View
Expert View

Ovation Pharmaceuticals' Sabril recommended by FDA panel despite reports of visual field defect

Ovation Pharmaceuticals has announced that an FDA advisory committee has voted unanimously to recommend Sabril (vigabatrin) for the treatment of two severe forms of epilepsy. If approved, Sabril will be the first FDA-approved monotherapy for infantile spasms. However, low historic uptake in the EU and concerns regarding visual field defects suggest that the drug's commercial prospects are limited.

Published By Datamonitor
12 Jan 2009
CommentWire
CommentWire

Nycomed/Merck: Daxas deal will have limited financial impact

Nycomed and Merck & Co. have agreed to co-promote the novel COPD therapy Daxas, which recently gained a positive recommendation in the EU. While this collaboration boosts Daxas' commercial prospects in several European countries, as well as Canada, the drug is limited by its restricted patient potential.

Published By Datamonitor
28 Apr 2010
CommentWire
CommentWire

Novartis: FDA refusal may relegate Menveo to second-to-market for toddlers

Novartis has announced the US approval of its licensed quadrivalent meningococcal vaccine, Menveo, in children aged two to 10; however, the FDA rejected an application for younger age groups. This represents a major setback for the firm, which is already struggling to gain share in the US meningococcal market due to the dominance of Sanofi Pasteur's competitor Menactra.

Published By Datamonitor
07 Feb 2011
CommentWire
CommentWire

NicOx: FDA approval a step closer for naproxcinod, but marketing partner remains elusive

NicOx has filed a New Drug Application for osteoarthritis treatment naproxcinod to the FDA. While Datamonitor expects a positive decision, the success of the drug will hinge on NicOx obtaining a marketing partner, as the company currently has inadequate resources to commercialize naproxcinod on its own in the competitive and highly genericized US osteoarthritis market.

Published By Datamonitor
28 Sep 2009
CommentWire
CommentWire

NicOx/AstraZeneca: NO-Naproxen announcement stuns partner

Hopes for the leading compound in the CINOD class of arthritis drugs have been dealt a serious blow after it failed to live up to expectations in phase II trials. AstraZeneca may now pull out of its partnership with the drug's developer, NicOx. Although great things had been anticipated for the drug, it now seems highly unlikely that it will challenge the leading COX-II inhibitors.

Published By Datamonitor
28 Feb 2003
CommentWire
CommentWire

NicOx/AstraZeneca: a new class of pain medication

NicOx's HCT 3012 is a new class of analgesic and anti-inflammatory drug, with a superior gastrointestinal safety profile compared to naproxen. With AstraZeneca's backing, this product has the marketing strength to compete with Pharmacia and Merck - who currently dominate the non steroidal anti inflammatory drugs (NSAID) market.

Published By Datamonitor
23 May 2002
Expert View
Expert View

Multiple Sclerosis: the search for a vaccine continues

There are approximately 250,000 to 350,000 diagnosed cases of multiple sclerosis in the US, yet it is estimated that the actual number of Americans with MS may be even higher. As a new approach to the treatment of MS, vaccines have the potential to be both efficacious and cost effective. But can a vaccine be developed as a viable treatment for MS?

Published By Datamonitor
02 Aug 2002
ResearchWire
ResearchWire

Multiple sclerosis: new treatments will take on interferons

Published By Datamonitor
14 Mar 2001
ResearchWire
ResearchWire

Monoclonal antibodies: sales to increase six-fold by 2005

Published By Datamonitor
19 Apr 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.